The purpose of this study is to assess the safety and tolerability of KRN951 administered to
patients with solid tumors. In the single dose period, patients in each cohort will receive
one oral dose of KRN951 in the first day, followed by a 6-day rest period during which no
treatment is received. After that, patients in each cohort will receive one oral dose of
KRN951 daily over a 21-day treatment period, followed by a 7-day rest period during which no
treatment is received. Treatment will be continued in the absence of disease progression or
unacceptable adverse events.
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.